Here are 6 ASX stocks at 12 month highs, and whether it is time to buy

Here are 6 ASX stocks at 12 month highs!

 

Liontown Resources (ASX:LTR)

Liontown’s Kathleen Valley has been producing since the second half of last year. It has a current Mineral Resource Estimate of 156Mt at 1.4% lithium and could produce over 500ktpa over a 23-year life of mine. Trouble is, lithium prices have led to investors shunning the sector.

That said, the company is in better shape than a year ago. Last year CEO Tony Ottaviano openly called for government support in the form of royalty relief. This year, the company can boast of nearly 300,000dmt in lithium, is ramping up production further and raised over $300m in fresh capital. $50m of this came from the National Reconstruction Fund Corporation – a Commonwealth entity that invests in project’s like Liontown’s.

And the company’s pleas for tax relief was partially met – it was termed eligible for a waiver of port charges and rebates for certain mining tenement fees for either two years or when the spodumene concentrate exceeds U$1,100 for two straight quarters.

Ultimately the company won’t reach its full potential until lithium prices sustainably recover. There are some green shoots – in operational troubles at CATL’s Jianxiawo mine in China which will see production halted for 3 months – but this is not the first time we’ve seen signs like this in the last few years. Time will tell.

 

Lumos Diagnostics (ASX:LDX)

Lumos is the company behind FebriDx is the only rapid, all-in-one point-of-care test on the planet that can distinguish a clinically significant acute respiratory infection (ARI) and differentiate viral from bacterial infections.

Back in July, Lumos announced a pivotal, exclusive US supply and distribution deal for FebriDx valued at up to US$317m/A$487m from PHASE Scientific International. Under the terms of the deal, Lumos received a US$1m non-refundable exclusivity payment on signing and was promised US$7.5m in non-refundable prepaid purchase orders.

The total value could be US$317m if all payment milestones aforementioned and minimum order quantities are met. This is one of the largest distribution deals of its type to be done by an ASX-listed point of care company.

There could be even more good news to come in the coming months. Lumos is undertaking a CLIA waiver study to enable FebriDx to be used in a broader range of settings (i.e. outpatient clinics). The company expects to finish the study soon with a FDA CLIA waiver to be submitted a month after that.

CLIA is the Clinical Laboratory Improvement Amendments, which set standards for laboratory testing quality, safety and accuracy. Some products may be waived if they are simply to use and the risk of wrong results are low. This would be terrific for Lumos if it could get this.

 

Artrya (ASX:AYA)

Back in April 2025, Artrya got its first FDA approval. The company’s flagship Salix product is the Salix Coronary Anatomy (SCA) which uses AI to provide clinicians with the rapid reporting of vulnerable plaque – a strong predictor of heart attacks because excess plaque can cause the walls of coronary arteries to rupture.

Vulnerable plaque is one of the strongest predictors of heart attacks, but it’s difficult and time-consuming to identify manually, even if you have enough physicians (which isn’t always the case). SCA generates a personalised 3D heart model depicting the extent of plaque and other biomarkers. It can do the job with just an internet connection and in 15 minutes.

There is a big opportunity in the USA – a country where there is one heart attack every 40 seconds. Artyra reckons it has a US$4.4bn opportunity in the form of 4.4m CCTA scans done. Moreover, the US has attractive reimbursement rates (i.e. starting from US$950) and minimal competition – there has been little to no innovation for detecting CAD in decades.

 

Ventia (ASX:VNT)

Ventia is an infrastructure maintenance services provider that relisted on the ASX immediately post-COVID. It has repeatedly impressed investors with its financial results. In 2024, delivered a $227.9m profit, up 13%, from $6.1bn in revenue, up 7.6%. It provided FY25 guidance of 7-10% profit growth.

Also impressive has been individual deals. Just prior to Christmas, the company announced a five-year partnership with Telstra that would be anticipated to generate $400m in revenue over the next 5 years.

 

Nick Scali (ASX:NCK)

What’s the story here? Is the COVID furniture boom still going on? No, it’s gone. Its results for FY25 weren’t that impressive – its underlying profit shrank by a quarter.

But we think investors are excited about this company’s expansion in the UK. In April last year, it bought Fabb Furniture for $46m and claimed there was an A$24bn opportunity. In 2025, it launched its online brand and boasted $41.8m revenue vs $8.3m the year before. It told investors it expected the refurbishment and rebranding of all UK stores that hadn’t yet been to be completed by the end of this calendar year.

It is also not shying away from Australia saying there was a long-term opportunity of up to 86 NCK stores.

 

Pantoro Gold (ASX:PNR)

Any gold stock is doing well right now. But not all of them are at 12-month highs like Pantoro is. It has been only 2 years since it bought Tulla Resources which was its 50% co-owner in relation to the Norseman gold project in WA which has 4.7Moz gold.

At this years’ Diggers and Dealers conference, it boasted of a strong FY25 with over 80koz produced and $80m EBITDA for the year. It told investors big things were ahead, aiming for >100koz production for the year and it had a $55m budget to spend on growing the resources.

 

What are the Best ASX Stocks to invest in right now?

Check our ASX stock buy/sell tips